Abstract | OBJECTIVE: METHODS: Seventy seven patients were randomly assigned to the two treatment groups: Group A ( phototherapy) and Group B ( azelastine). Subjective and objective outcomes were represented by changes in Total Nasal Symptom Score (TNSS), Quality of life scores (Rhinoconjunctivitis Quality of Life Questionnaire - RQLQ), and nasal resistance. RESULTS: The study demonstrated that both azelastine and intranasal phototherapy are able to significantly improve TNSS, including individual nasal symptoms. Nevertheless, phototherapy reduced nasal obstruction better than azelastine (p=0.038). Both treatments were highly effective in improving RQLQ scores overall and in seven separate domains. CONCLUSION: Whether intranasal phototheraphy will be a standard treatment of SAR or not should be appraised in future studies and clinical trials.
|
Authors | Silviu Albu, Sorin Baschir |
Journal | Auris, nasus, larynx
(Auris Nasus Larynx)
Vol. 40
Issue 5
Pg. 447-51
(Oct 2013)
ISSN: 1879-1476 [Electronic] Netherlands |
PMID | 23228884
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2012 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Phthalazines
- azelastine
|
Topics |
- Administration, Intranasal
- Adult
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Phototherapy
(methods)
- Phthalazines
(therapeutic use)
- Rhinitis, Allergic, Seasonal
(therapy)
- Surveys and Questionnaires
- Treatment Outcome
- Young Adult
|